Citizens Highlights Kura Oncology’s (KURA) KO-2806 Potential, Reiterates at Outperform

Citizens analyst Reni J. Benjamin reiterated a Market Outperform rating and $24.00 price target on Kura Oncology (NASDAQ: KURA).

The analyst commented, "We reiterate our Market Outperform rating on Kura Oncology and our price target of $24, which is based on a blended discounted EPS and revenue multiple analysis. Kura's ESMO 2025 presentations provide the first clinical look at KO-2806 (darlifarnib), a next-generation farnesyl transferase inhibitor (FTI) positioned as a combination partner for targeted therapies. The data highlight KO-2806's ability to overcome resistance in solid tumors, resensitizing refractory tumors to the multi-kinase inhibitor cabozantinib (cabo) and boosting efficacy in naive patients. Given KO-2806's safety profile and strong potential to synergize with established inhibitors, the ESMO data suggest a broad market opportunity not factored into the current valuation, in our view. With zifto on track for approval by November 30, 2025, Phase 1b KOMET-007 trial data expected at the 2025 ASH conference, and a pro forma cash position of $730.7MM, we continue to view the company as attractively valued, now with a free option for further upside beyond the zifto opportunity."

For an analyst ratings summary and ratings history on Kura Oncology click here. For more ratings news on Kura Oncology click here.

Shares of Kura Oncology closed at $9.84 yesterday.

You May Also Be Interested In

• Stripe, Advent In Talks To Buy Paypal - WSJ
• Home Depot (HD) call put ratio 1.5 calls to 1 put with a focus on September 330 puts into quarter results
• Full Circle Lithium closes $5.14M private placement